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Interest in transfusion-associated Cytomegalovirus (CMV) infections began with
the recognition that the overwhelming majority of cases of late-onset postperfusion
mononucleosis were heterophile negative (1, 2). In 1965 Klemola and Kaariainen (3)
associated heterophile-negative mononucleosis with CMV infection, and 1 year later
the same group documented the association ofCMV infection with heterophile-nega-
tive posttransfusion mononucleosis (4). Those patients experiencing CMV infection
had not undergone extracorporeal perfusion but had been transfused with large
volumes of fresh blood, which implied that asymptomatic carriage ofCMV might be
quite common. This supposition seemed to be borne out by Diosi et al. (5) in work
published in 1968 which reported CMV isolation from the peripheral leukocytes of2
out of 35 healthy blood donors. Since that time peripheral leukocytes from over 1500
blood donors have been inoculated into cell culture for virus isolation, but no CMV
has been recovered. This work has been done in various parts of the world including
Bristol, England (6), Pittsburgh (7), Cleveland (8), Atlanta (9), Houston (10), Kansas
City (11), and Seattle (12).
Prospective studies have examined the incidence of CMV infection by serology in
patients receiving multiple blood transfusions. Table 1, taken from Randall and
Plotkin (13), lists these studies which have shown posttransfusion infection fre-
quencies ranging from 21 to 38%. It is noteworthy that 10 to 15% of those infected
developed the postperfusion syndrome. At this point it is important to emphasize the
difference between infection and disease. "Disease" is a very simple English word
that means just what it says.... dis - ease, or loss of comfort. "Infection", on the
other hand, means the establishment of a host-parasite interaction and need not lead
to damage to the host. There are many ways of detecting this interaction, ranging
from isolation of the agent to evidence of the immunological response in the host.
This table shows evidence ofinfection.
Table 2 is taken from a paper by Krech (18) and shows the distribution of CMV
complement Fixing (CF) antibodies in healthy blood donors in different parts of the
world. Antibody prevalences range from 40% in highly industrialized areas to 100%
in developing countries. It is interesting that antibody prevalences in Japan and Hong
Kong are in excess of90%, even though they cannot be considered developing areas.
Table 3 is a summary ofCMV CF antibody prevalence studies in blood donors liv-
ing in Europe, Australia, and North America. The low prevalence reported in the
study of Monif et al. (24) can be explained by the fact that the majority of the donors
in Gainesville are college students, thus young and likely to be middle class. Addi-
tional studies reporting low antibody prevalences are those of Jack and McAuliffe
5
Copyright © 1976 by Academic Press, Inc.
All rights ofreproduction in any form reserved.BAYER AND TEGTMEIER
TABLE I
Incidence ofCMV Antibody Rise (CF) in Patients Receiving Multiple Blood
Transfusions from Randall and Plotkin (13)
Number
Number ofpatients
Study ofpatients with rise Percentage
Princeetal., 1971 (14) 72 15 21
Henleetal., 1970(15) 72 17 23
Stevens et al., 1970 (16) 41 13 32
Perham etal., 1971 (6) 55 21 38
Paloheimo etal., 1968 (17) 63 19 30
(19) and Embil et al. (21). Only the study of Mirkovic et al. (10) reported relatively
high antibody prevalence. A skewed age distribution of donors does not appear to be
the explanation for the low prevalences cited in the two former studies, nor is it
responsible for the high prevalence reported in the Houston study. Socioeconomic
factors may explain these differences.
From June, 1972 to February, 1973 we conducted a study at the Community Blood
Center aimed at defining the epidemiology of CMV infections among blood transfu-
TABLE 2
Distribution ofCytomegalovirus Complement-Fixing Antibodies among Healthy Blood Donors in
Different Parts ofthe World from Krech (18)
Number Samples with
of complement-fixing serum ~~~antibody Place where blood Country samples
was collected code tested Numbera Percentage
Lyon F 98 39 40
Freiburg D 89 37 42
St. Gallen CH 105 47 45
Albany USA 98 44 45
Melbourne AUS 99 54 54
Stockholm S 99 60 60
Manchester GB 94 58 61
Honolulu USA 145 97 67
Johannesburg (whites) SA 96 72 75
Houston USA 98 77 79
Buenos Aires RA 43 35 81
Bratislava CS 100 83 83
Port ofSpain TT 99 86 86
Mauritius MS 93 83 89
Anchorage USA 100 94 94
Hong Kong HK 99 94 94
Sendai J 99 96 96
Greenland DK 90 88 98
Dar es Salaam EAT 117 114 98
Morocco MA 109 107 98
Fiji Islands GB 95 95 100
Entebbe EAU 143 143 100
Ibadan WAN 95 95 100
Johannesburg (Bantu negroes) SA 112 112 100
Manila PH 89 89 100
Chandigarh IND 68 68 100
> I in 4. The tests were performed by the coordinating laboratory.
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TABLE 3
Prevalence ofComplement-Fixing Antibodies to CMV in Blood Donors
Reciprocal
oflowest
serum
dilution Prevalence
Study Year tested Geographic region (%)
Jack and McAuliffe (19) 1968 8 Melbourne, Australia 24
Baron et al. (20) 1969 10 Pittsburgh, Pennsylvania 60
Diosi et al. (5) 1969 8 Timisoara, Rumania 65
Embil et al. (21) 1969 8 Nova Scotia, Canada 38
Klemola et al. (22) 1969 4 Helsinki, Finland 66
Collaborative (23) 1970 NSa Manchester, England 56
Mirkovic etal. (10) 1971 10 Houston, Texas 75
Perham et al. (6) 1971 8 Bristol, England 55
Wentworth and Alexander (12) 1971 8 Seattle, Washington 52
Monifet al. (24) 1973 8 Gainesville, Florida 21
Kane et al. (11) 1975 8 Kansas City, Missouri 59
aNS, not stated.
sion recipients (11). In the Kansas City metropolitan area our 100% volunteer donor
base is really from the mainstream of society. It had a mean family income of
$14,000 in 1972 which has obviously increased with inflation. Our donors are 97%
Caucasian. Our black donor base is similar to our white donor base when compared
in terms of HB, Ag and anti-HB, prevalence.
Attendant to this study we examined the prevalence of CMV antibodies, viremia,
and viruria among 223 volunteer blood donors and followed the recipients of blood
from infected donors. The donors ranged in age from 19 to 62 with a mean of 37
years. They were 98% Caucasian and 77% were males. No CMV isolations were
made from any of the 223 leukocyte-rich plasmas or washed leukocytes inoculated
TABLE 4
Laboratory Data on Seven Blood Donors with Cytomegaloviruria from Kane et al. ( 11)
Reciprocal
Urine antibody titer
Donor Age/sex Time culture CFa IHAb
012 25-M Donation +d (23)c 16 160
6 weeks later Oe 16 160
025 38-M Donation + (22) 16 40
10 weeks later 0 16 40
029 28-M Donation + (13) 32 80
9 weeks later 0 32 80
123 37-M Donation + (27) 8 40
14 weeks later 0 16 40
162 51-M Donation + (21) 64 160
190 56-F Donation + (21) 8 80
8 weeks later 0 16 80
198 53-M Donation + (31) 32 40
8 weeks later 0 32 40
Complement fixation.
bIndirect hemagglutination.
cNumber ofdays in culture when viral cytopathogenicity first observed.
d+, CMV isolated.
e0, CMV not isolated.BAYER AND TEGTMEIER
TABLE 5
Complement Fixing Antibody Titers of223 Blood Donors from Kane et al. (I 1)
Number Number ofdonors
of Positivea with titer
Age donors (%) < 8 8 16 32 64
19-24 26 19 21 1 4 0 0
25-29 46 48 24 2 10 8 2
30-39 68 57 29 7 22 10 0
40-49 45 76 11 8 13 9 4
50-62 38 79 8 9 9 10 2
Total 223 58 93 27 58 37 8
aAntibody titer > 1:8.
directly onto Wentworth's human fetal tonsil fibroblasts. Seven donors (3%) were
cytomegaloviruric, and Table 4 summarizes the laboratory data on these donors.
Follow-up blood and urine cultures were taken from six of the seven
cytomegaloviruric donors at times ranging from 6 to 14 weeks after donation; none of
the cultures was positive for CMV. All viruric donors were antibody positive by CF
and indirect hemagglutination (IHA) and their titers remained unchanged in those
who were followed after donation. Their titers did not differentiate them from the
nonviruric donors. Table 5 shows that 58% of all the donors had CMV CF titers of
1:8 or greater, while Table 6 documents that 59% of this group had IHA antibody
titers of 1:10 or greater. When the CF and IHA titers from each donor were com-
pared, the direct correlation illustrated in Table 7 was found. Six of the seven units
taken from viruric donors were transfused, but only three of the six recipients lived
long enough to be followed for evidence of CMV infection. Table 8 summarizes the
laboratory data on the recipients of blood from the viruric donors. Two underwent
coronary artery bypass surgery, while the third was transfused during a gunshot
wound repair. Each of the recipients showed serologic evidence ofCMV infection by
a fourfold rise in IHA titer 13 to 16 weeks after transfusion. CMV-specific IgM anti-
bodies were detectable in the posttransfusion sera of two of the recipients. No post-
transfusion serum was available for testing from the third recipient. Somewhat puz-
zling was the fact that CF antibody rises were not detected in the two recipients on
whom sufficient quantities of serum were available for testing. CMV was isolated
from the urine of one of the recipients 14 weeks after transfusion. No disease at-
tributable to CMV infection was seen in any of the recipients of blood from the
viruric donors.
TABLE 6
Indirect Hemagglutination Antibody Titers of223 Blood Donors from Kane et al. (11)
Number
Number
of Positivea ofdonors with titer
Age donors (%) < 10 10 20 40 80 160 320 > 640
19-24 26 23 20 0 2 0 3 1 0 0
25-29 46 50 23 0 4 2 7 6 2 2
30-39 68 59 28 0 3 9 16 8 2 2
40-49 45 76 11 0 1 7 10 7 7 2
50-62 38 76 9 0 0 5 8 7 7 2
Total 223 59 91 0 10 23 44 29 18 8
aAntibody titer > 1:10.
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TABLE 7
Distribution of223 Donors by Indirect Hemagglutination (IHA) and
Complement Fixing (CF) Antibody from Kane et al. (11)
Reciprocal Reciprocal CF titer
IRA____________________
titer < 8 8 16 32 64
> 640 0 0 1 4 3
320 0 1 8 6 3
160 0 2 14 11 2
80 0 10 23 11 0
40 0 9 9 5 0
20 4 4 2 0 0
10 0 0 0 0 0
< 10 89 1 1 0 0
The observation of CMV infection in three recipients of blood from
cytomegaloviruric donors prompted us to continue our search for viruric donors in
order to see ifviruria rather than viremia might be a more reliableindicator ofability
to transmit CMV infection via blood. We have followed an additional 420 donors for
evidence of CMV infection by urine culture and serology. Only four donors (1%)
were excreting CMV in their urine at the time of donation. Antibody prevalence to
CMV by CF and IHA was 65% in this cohort. Two of the four units from viruric
donors were transfused to patients who could be followed, and the recipients had
pre-existing CMV CF antibody titers of 1:8 and 1:16, respectively. Neither recipient
showed evidence of infection by virus isolation from the urine or by fourfold or
greater rise in antibody titer. Thus, three of five recipients of blood from viruric
donors have shown evidence ofCMV infection subsequent to transfusion. This study
is still in progress and will continue until larger numbers of recipients have been
studied. We are also following recipients of blood from nonviruric donors who are
matched by age, sex, hospital, and medical history to the patients receiving blood
from cytomegaloviruric donors.
The large number of studies cited previously (6-1 1) which have unsuccessfully at-
tempted to isolate CMV from the leukocytes of normal donors stands in sharp
TABLE 8
Laboratory Data on 3 Recipients ofBlood from Cytomegaloviruric Donors from Kane et al. ( 11)
Reciprocal CMV
antibody titer
Virus culture IHA-
Recipient Age/sex Time Blood Urine CFa IHAb IgMC
025R 61-F Pretransfusion _d - 32 320 < 8
9 weeks later 0 0 32 640 32
16 weeks later 0 0 32 1280 64
162R 48-M Pretransfusion - - 16 80 < 8
13 weeks later - - 32 320 QNS
198R 38-M Pretransfusion - - QNS 40 QNS
14 weeks later 0 + 128 320 8
aComplement fixation.
bIndirect hemagglutination.
d IHA antibody titerofserum fraction containing IgM.
+, CMV isolated; 0, CMV notisolated;-, not performed.
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contrast to the report of Diosi et al. (5) who identified two asymptomatic donors with
CMV viremia out of 35 tested. This may well have been a chance observation, but
Diosi's methods were sufficiently different from those reported in the other studies
that this factor could be responsible for the disparate results. In order to test this
hypothesis, we obtained blood and urine samples from 120 donors and attempted to
isolate CMV by closely following the procedures described in Diosi's paper. The pro-
tocol involved culturing the leukocytes in suspension for 72 hr prior to inoculating
them onto cultures of human fetal fibroblast cell cultures. In addition, we cultured
three aliquots of cells from each donor in Diosi's medium which contained 10 ug/ml
dexamethasone, 10 ,ug/ml azathioprine, and 2% antilymphocyte serum, respectively,
for 72 hr and then inoculated the treated leukocytes onto human fetal tonsil cell
cultures. The rationale for doing this was that drug treatment might unmask latent
CMV resident in the leukocytes of the donors. Of 120 donors, 71 (59%) had CMV
IHA antibody titers of 1:10 or greater, but no CMV was isolated from the untreated
or drug-treated leukocytes of any donor. Three antibody-positive donors (2.5%) were
excreting CMV in their urine at the time of donation. Recipients of the blood from
these donors were not followed. In short, our data support the contention that
methodologic differences are not responsible for the failure of numerous investiga-
tors to isolate CMV from the leukocytes ofnormal donors.
Although specifically charged with discussing the blood donor, we want to present
some data on a group ofopen-heart patients who were prospectively followed for evi-
dence of CMV infection. The number of open heart surgeries performed in Kansas
City in 1972 was 827. This figure increased to 1199 in 1973 and climbed to 1289 in
1974; however, the average number of units used per case has declined from a figure
of six in 1973 to four in 1974, and is about three units per case this year. Two units of
fresh blood are made available for each surgery, but actual transfusion of units less
than 2-days-old occurs only 15% of the time. Most of the blood transfused in heart
surgery is 3- to 8-days-old, and approximately 18% ofthe transfused units are over 10
days old. Table 9 shows the results of our first study on open-heart patients which
was done in Hospital A. The 35 patients in this study received an average of5.8 units
of blood. Throat, urine, and blood samples were collected for virus isolation and
serology prior to surgery and at 6 and 12 weeks after surgery. Clinical data were ob-
tained from the patient's cardiologist or his family physician. Three of 35 patients
(9%) showed serologic evidence of CMV infection both by IHA and CF tests. Al-
though CMV was isolated from the urine of one of these three patients at 12 week
follow-up, no virus isolations were made from any other specimens. No illnesses at-
TABLE 9
Serologic Response ofOpen Heart Patients to CMV as Monitored by CF and IHA Tests, Hospital A
Number
Serologic Status ofpatients Percentage
a Negative, no change in antibody titer 2 6
Pre-existingantibodies,b no change in titer 30 86
Conversionc 1 3
Pre-existing antibodies, fourfold or
greater rise in antibody titer 2 6
Totals 35 100
aNegative means a serum antibody titer of < 1:8 by CF or < 1:10 by IHA.
bPre-existing antibodies mean a serum antibody of > 1:8 by CF or 1:10by IHA.
Conversion means a change in titer from < 1:8 to > 1:16by CF or < 1:10 to > 1:20by IHA.
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TABLE 10
Serologic Response ofOpen Heart Patients to CMV as Monitored by CF and IHA Tests, Hospital B
Number
Serologic Status ofpatients Percentage
a Negative, nochange in antibody titer 5 25
Pre-existing antibodies,b no change in titer 15 75
Conversionc 0 0
Pre-existing antibodies, fourfold or
greater rise in antibody titer 0 0
Totals 20 100
Negative means a serum antibody titer of < 1:8 by CF or < 1:10 by IHA.
b Pre-existing antibodies mean a serum antibody of > 1:8 by CFor> 1:10 by IHA.
Conversion means a change in titer from < 1:8 to > 1:16 by CF or < 1:10 to > 1:20 by IHA.
tributable to CMV were seen in any of the three patients experiencing CMV infec-
tion.
Our second study of open-heart patients, still in progress at Hospital B, has the
same design as the one previously described. Table 10 displays the preliminary
results of this study. Twenty patients have been followed, and none has shown evi-
dence ofCMV infection. An average of2.5 units ofblood was used for each case.
To evaluate the relative risk of CMV infection after transfusion with antibody-
positive and antibody-negative blood, we have been studying the recipients ofone and
two unit transfusions (where both donors are either antibody positive or antibody
negative). The data accumulated to date are presented in Table 11. The number of
patients followed is small, and therefore no conclusions can be drawn. Only 1 of 32
recipients has shown evidence of CMV infection. The patient, who had a presurgical
CMV CF titer of64, received two CMV antibody-positive units during hysterectomy
and showed a fourfold rise and viruria at 12 weeks follow-up. No disease was seen in
this patient.
In summary, transfusion-associated cytomegalovirus disease is not an obvious
problem in this community, at least in terms ofadult transfusions. Two factors which
are responsible for the apparent absence of disease and the low frequency of CMV
infections are excellent surgeons who use very little blood in their operative
procedures and the high quality of the blood donor base in the Kansas City
metropolitan area.
TABLE 11
Serologic Response to CMV ofSingle and Double Unit Transfusion Recipients
Antibody Conversions No change
Number Pretransfusion status or in
of Percent- antibody of fourfold antibody
recipients age status donor blood rises status
17 53 Positivea Positive 1c 16
11 34 Positive Negativeb 0 11
3 9 Negative Positive 0 3
1 3 Negative Negative 0 1
Totals
32 100 1 31
Positive is defined as a serum antibody of > 1:8 by CF or > 1:10 by IHA.
b Negative is defined as an antibody titer of > 1:8 by CF and > 1:10 by IHA.
CCMV was isolated from the recipient's urine at 8 weeks follow-up.
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